Watchmaker Genomics specializes in advanced enzymology to enable applications for reading, writing, and editing DNA and RNA. The company established an enzyme‑engineering technology platform in 2019 that leverages computational design and directed evolution. Its founding team has deep domain expertise in next‑generation sequencing and clinical oncology assay development and previously built companies including Kapa Biosystems, Enzymatics, and ArcherDx. Watchmaker launched its first product in 2020 and has since achieved profitability with 175% year‑over‑year revenue growth. With the new financing it plans to accelerate investment in its protein engineering platform to deliver a suite of products for clinical sequencing and emerging applications such as single‑cell analysis, epigenetics, and cell‑free DNA. The company will also expand commercial channels and manufacturing capacity to make its product solutions more broadly accessible to the life‑science and genomics communities.

Total raised

$40M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2022